Join our daily newsletter At The Bell to receive exclusive market insights
- Regenerative medicine company Regeneus (RGS) has been granted a U.S. patent for its Progenza stem cell treatment
- This patent covers a broad range of inflammatory conditions, such as arthritis, asthma and autoimmune conditions
- Progenza is the company’s leading cell therapy technology, which uses stem cells from human connective tissue
- It works by reducing inflammation and promoting healing and repair in the damaged or diseased tissue
- Regeneus shares are up 6.15 per cent on the market and currently trading for 6.9 cents each
Regenerative medicine company Regeneus (RGS) has been granted a U.S. patent for its Progenza stem cell treatment.
This new patent covers the treatment of inflammatory conditions using stem cells. These include inflammatory conditions caused by a wide range of conditions such as arthritis, heart disease, asthma, and autoimmune conditions.
The patent for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19.
ARDS is also a common cause of respiratory failure in critically ill patients, however, there is no pharmaceutical treatment currently available.
“While Regeneus’ focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio,” CEO and Executive Director Leo Lee said.
“It also opens doors to form partnerships for Progenza for other disease and indications,” he added.
The Prozenga treatment
Progenza is made from allogeneic mesenchymal stem cells (MSCs) from human connective tissues. It contains bioactive secretions from cells which have shown increased therapeutic benefit.
These cells are adult stem cells that have not be reprogrammed or genetically altered in any way during the manufacturing process.
Progenza then works by reducing inflammation and promoting healing and repair in the damaged or diseased tissue.
A Phase I trial has already been completed successfully with the primary safety endpoints met and efficacy showing significant reduction in knee pain and improvement in cartilage movement.
Regeneus shares are up 6.15 per cent and trading for 6.9 cents each at 3:03 pm AEDT.
